Cefazolin Sodium

B Braun’s Duplex system is engineered to minimise the risk of contamination and medication errors. Credit: Bendix M/Shutterstock. The US Food and Drug Administration (FDA) has approved the injectable antibiotics Piperacillin and Tazobactam for use in B Braun Medical’s Duplex drug delivery system. The drug delivery system is a ready-to-activate container that separates pre-measured medication and diluent until activation by the provider during treatment. The system decreases process time by around four minutes for each dose and saves considerable labour time in comparison to the Baxter Mini-Bag Plus container system and traditional compounding methods. B Braun’s Duplex system is engineered to minimise risks of contamination and medication errors. Its closed-system design protects the potency of the drug and ensures that the diluent cannot be administered without the medication. With fewer process steps, the system has been shown to decrease the possibility of medication errors by 54% versus traditional compounding. The system eliminates the need for thawing and is suitable for storage at room temperature or in automated dispensing cabinets. B Braun medical marketing senior director Jeremy Greene stated: “We are excited to introduce Piperacillin and Tazobactam in our innovative Duplex drug delivery system, designed to save time, labour and space, and reduce waste. “Enhancing efficiency for nurses and pharmacists aligns with our commitment to providers and the patients they serve.” This is B Braun’s second introduction of antibiotics into the drug delivery system in 2025, following the launch of Cefazolin 3g, and is part of the company’s strategy to expand its portfolio of injectable drugs in the US. Headquartered in Pennsylvania, the company specialises in pharmacy products and infusion therapy.

B. Braun Medical Inc. has announced that the US Food and Drug Administration (FDA) has approved Piperacillin and Tazobactam, one of the most utilised injectable antibiotics in the US for use in the Company's DUPLEX® Drug Delivery System, and will begin moving toward a full launch. Piperacillin and Tazobactam in the DUPLEX Drug Delivery System is a ready-to-activate, two-compartment container that keeps pre-measured medication and diluent separate until the provider is ready to administer at the bedside by simply folding, squeezing, and shaking to reconstitute. This system reduces overall process time by nearly four minutes per dose and shows substantial labor time savings compared to both the Baxter Mini-Bag Plus Container System and traditional compounding, offering healthcare professionals a new and efficient way to administer this critical antibiotic combination. DUPLEX is also designed to reduce contamination risks and medication errors. The closed-system design helps protect potency and ensures the diluent cannot be delivered without the drug. Furthermore, DUPLEX decreases the likelihood of medication errors by 54 percent compared to traditional compounding methods based on fewer process steps. DUPLEX requires no thawing and can be stored at room temperature or in automated dispensing cabinets. "We are excited to introduce Piperacillin and Tazobactam in our innovative DUPLEX Drug Delivery System, designed to save time, labor, and space, and reduce waste," said Jeremy Greene, Senior Director of Marketing at B. Braun Medical. "Enhancing efficiency for nurses and pharmacists aligns with our commitment to providers and the patients they serve. And, the DUPLEX Container is not made with DEHP or PVC, further protecting patients and the environment," added Greene. Piperacillin and Tazobactam in the DUPLEX Drug Delivery System will mark the second DUPLEX Drug launch in 2025 (in addition to Cefazolin 3g) and is one of many planned injectable drugs B. Braun will launch in the U.S. in the next several years to expand its portfolio and help meet the needs of patients for medications in high demand.